The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to ...

Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses how the "multiple confidential discussions" ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical ...